Roche and Zuellig Pharma Extend Philippines Distribution Partnership Into Sixth Decade

A Half-Century Alliance Renewed

Roche Philippines and Zuellig Pharmaceuticals have extended their distribution partnership, cementing a supply relationship that has operated continuously since 1972. The renewal marks 54 years of collaboration in a market where geographic fragmentation and infrastructure gaps remain persistent obstacles to pharmaceutical delivery.

The agreement was formalized at a signing ceremony in Manila, attended by Diana Edralin, general manager of Roche Philippines, and Manuel Dizon, market director at Zuellig Pharma. The partnership centers on warehousing and distribution services for Roche's portfolio, which includes treatments for oncology, immunology, and rare diseases.

Zuellig Pharma has maintained operations in the Philippines for 103 years, making it one of the longest-standing healthcare services providers in the country. The firm operates across 13 Asian markets and handles distribution for multinational pharmaceutical manufacturers seeking reach into fragmented Southeast Asian geographies.

Supply Chain Stakes in a Fragmented Market

The Philippines presents unique logistical challenges for pharmaceutical distribution. The country comprises more than 7,600 islands, with significant population centers scattered across Luzon, Visayas, and Mindanao. Cold-chain infrastructure remains inconsistent outside Metro Manila, and last-mile delivery to provincial hospitals and clinics often requires multi-modal transport.

For Roche, continuity of distribution is critical. The company's oncology and rare disease therapies typically require temperature-controlled storage and tight expiration windows. Any disruption in the supply chain can delay treatment for patients with limited alternatives.

According to Edralin, the renewed partnership is designed to ensure that life-saving medicines reach Filipino patients efficiently. Zuellig Pharma's network includes over 400 distribution points nationwide, supported by a fleet of refrigerated vehicles and a digital inventory management system.

Dizon emphasized the historical weight of the relationship. "Zuellig has been in the Philippines for 103 years. Of those 103 years, 54 years have been in partnership with Roche," he said at the signing. He described his role as that of a custodian, responsible for maintaining a relationship that has spanned more than half a century.

Strategic Priorities and Market Context

The renewal arrives as pharmaceutical multinationals face mounting pressure to improve access in emerging markets. In the Philippines, patient advocacy groups have long called for more reliable supply of specialty medicines, particularly for cancer and autoimmune conditions where treatment interruptions can be life-threatening.

Roche is a global leader in diagnostics and pharmaceuticals, with a strong presence in oncology and personalized medicine. The company's portfolio includes blockbuster therapies such as Herceptin and Avastin, as well as diagnostic platforms used in hospital laboratories across Asia.

Zuellig Pharma, headquartered in Singapore, is one of the largest healthcare services groups in the region. Beyond distribution, the company offers regulatory consulting, market access services, and digital health solutions. It has been expanding its capabilities in cold-chain logistics and data analytics, areas critical to supporting the next generation of biologics and cell therapies.

Both companies indicated that the renewed agreement will focus on optimizing logistics and embracing innovation to overcome the Philippines' geographic challenges. This includes potential investments in digital tracking, predictive inventory management, and expanded cold-chain capacity in secondary cities.

Looking Ahead

The partnership's longevity is notable in an industry where distribution agreements are frequently renegotiated or terminated as manufacturers seek cost efficiencies or direct-to-patient models. The 54-year tenure suggests mutual reliance: Roche benefits from Zuellig's established network and regulatory expertise, while Zuellig gains stable volume from a top-tier pharmaceutical manufacturer.

For the Philippines, the renewal offers continuity at a time when healthcare infrastructure is under strain. The country's aging population and rising incidence of non-communicable diseases are driving demand for specialty medicines, even as public health budgets remain constrained.

The agreement also signals confidence in the Philippine market's long-term growth trajectory. Despite economic volatility and regulatory complexity, the country remains a priority for multinational pharmaceutical companies seeking scale in Southeast Asia.

As both parties look toward the next chapter, the focus will be on translating decades of operational experience into measurable improvements in patient access, particularly in underserved regions where healthcare delivery remains a persistent challenge.